GlassScriptPhysician profile
Nadia Khoury
NPI 1346446143
$32,641.65
in general payments reported to CMS, 2019-2025
68 companies · $4,136 in 2025
The $4,136 reported for 2025 was more than what 86% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $2,655 · 2021: $3,627 · 2022: $3,748 · 2023: $3,720 · 2024: $3,906 · 2025: $4,136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,741.21 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $4,606.44 | 2019-2023 | Tepezza |
| Novo Nordisk INC | $4,223.43 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $3,180.06 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $1,925.70 | 2019-2025 | Tepezza, Repatha, Evenity |
| Corcept Therapeutics | $1,739.68 | 2019-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,527.67 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,274.93 | 2019-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $1,270.59 | 2019-2025 | |
| Tandem Diabetes Care, INC. | $962.42 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $873.70 | 2021-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $870.61 | 2020-2025 | Recorlev, Gvoke Hypopen, Keveyis |
| Abbvie INC. | $854.50 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $805.76 | 2021-2025 | |
| Abbott Laboratories | $667.37 | 2019-2025 | Freestyle Libre 3 |
| Antares Pharma, INC. | $573.15 | 2019-2025 | Xyosted, Tlando, Nocdurna |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadia Khoury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.